[Federal Register Volume 60, Number 102 (Friday, May 26, 1995)]
[Notices]
[Page 27981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-13032]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 95E-0055]
Determination of Regulatory Review Period for Purposes of Patent
Extension; FRAGMIN
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for FRAGMIN and is publishing this
notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Commissioner of Patents and Trademarks, Department of Commerce, for the
extension of a patent which claims that human drug product.
ADDRESSES: Written comments and petitions should be directed to the
Dockets Management Branch (HFA-305), Food and Drug Administration, rm.
1-23, 12420 Parklawn Dr., Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-443-1382.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Commissioner of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted as well as any time that may have occurred before the patent
was issued), FDA's determination of the length of a regulatory review
period for a human drug product will include all of the testing phase
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product
FRAGMIN (dalteparin sodium). FRAGMIN is indicated
for prophylaxis against deep vein thrombosis, which may lead to
pulmonary embolism, in patients undergoing abdominal surgery who are at
risk for thromboembolic complications. Subsequent to this approval, the
Patent and Trademark Office received a patent term restoration
application for FRAGMIN (U.S. Patent No. 4,303,651) from
Pharmacia Aktiebolag, and the Patent and Trademark Office requested
FDA's assistance in determining this patent's eligibility for patent
term restoration. In a letter dated March 23, 1995, FDA advised the
Patent and Trademark Office that this human drug product had undergone
a regulatory review period and that the approval of FRAGMIN
represented the first permitted commercial marketing or use of the
product. Shortly thereafter, the Patent and Trademark Office requested
that FDA determine the products's regulatory review period.
FDA has determined that the applicable regulatory review period for
FRAGMIN is 3,555 days. Of this time, 2,832 days occurred
during the testing phase of the regulatory review period, while 723
days occurred during the approval phase. These periods of time were
derived from the following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: March 31,
1985. The applicant did not state an investigational new drug
application (IND) effective date, stating that foreign studies were
used in lieu of an IND. However, FDA records indicate that certain
studies material to the approval of the product were conducted under
IND 25,924. Therefore, the IND effective date was March 31, 1985, which
was 30 days after FDA receipt of IND 25,924.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the Federal Food, Drug,
and Cosmetic Act: December 30, 1992. The applicant claims February 28,
1993, as the date the new drug application (NDA) for FRAGMIN
(NDA 20-287) was initially submitted, whereas it is actually the filing
date. FDA records indicate that NDA 20-287 was refused to file on
September 25, 1992. The correct resubmission date for NDA 20-287 is
December 30, 1992, which was the date the resubmission was actually
received by the agency. Therefore, the NDA initial submission date for
NDA 20-287 is December 30, 1992, the same as the resubmission date.
3. The date the application was approved: December 22, 1994. FDA
has verified the applicant's claim that NDA 20-287 was approved on
December 22, 1994.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 661 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may on or before July 25, 1995, submit to the Dockets
Management Branch (address above) written comments and ask for a
redetermination. Furthermore, any interested person may petition FDA,
on or before November 22, 1995, for a determination regarding whether
the applicant for extension acted with due diligence during the
regulatory review period. To meet its burden, the petition must contain
sufficient facts to merit an FDA investigation. (See H. Rept. 857, part
1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the
format specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch (address above) in three copies (except that
individuals may submit single copies) and identified with the docket
number found in brackets in the heading of this document. Comments and
petitions may be seen in the Dockets Management Branch between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: May 15, 1995
Stuart L. Nightingale,
Associate Commissioner for Health Afairs.
[FR Doc. 95-13032 Filed 5-25-95; 8:45 am]
BILLING CODE 4160-01-F
